School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran.
School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran.
Int J Biol Macromol. 2021 Mar 15;173:409-420. doi: 10.1016/j.ijbiomac.2021.01.067. Epub 2021 Jan 14.
Chitosan (CS)/polyvinylpyrrolidone (PVP)/hematite (α-FeO) nanocomposites loaded with Doxorubicin (drug model) were synthesized via an oil-in-water emulsification method to develop a biocompatible and pH-sensitive drug nanocarrier for the first time. A hydrogel, including CS, PVP, and α-FeO, was fabricated successfully with glutaraldehyde (GA) as the cross-linker. Incorporating α-FeO into CS/PVP hydrogel improved the pH-sensitivity and developed beneficial hydrogel. FTIR and XRD analysis illustrated physical interactions between polymer-polymer, polymer-drug, and crystalline behavior of prepared nanocomposite. These analyses also confirmed chemical bonding in nanocomposite's structure. The FE-SEM analysis showed successful impregnation of α-FeO into CS/PVP matrix and spherical structure. To clarify the size distribution and surface charge of the drug-loaded nanocomposite (CS/PVP/α-FeO/Dox), DLS and zeta analyses were conducted. They showed the mean size of nanocomposites at about 247 nm. Drug-loaded CS/PVP/α-FeO nanocomposite and CS/PVP/Dox were studied for their release behavior and kinetics. Furthermore, the effect of α-FeO on release from CS/PVP/α-FeO/Dox nanocomposite was investigated. That showed an increase in encapsulation of Doxorubicin and beneficial release behavior such as slow-release and retention effect. The release from this drug-loaded nanocomposite revealed excellent pH-sensitive and controlled release of the drug. Besides, the in vitro cytotoxicity and cell apoptosis were studied to recognize biological properties. These analyses revealed that drug-loaded nanocomposite caused high inhibition to MCF-7 cells in presence of α-FeO and proved the hematite's anti-cancer effect. By and large, this study confirmed CS/PVP/α-FeO nanocomposites as a potential candidate for the controlled pH-sensitive release of the drug.
壳聚糖（CS）/聚乙烯吡咯烷酮（PVP）/赤铁矿（α-FeO）纳米复合材料负载阿霉素（药物模型）通过油包水乳化法合成，首次开发出一种生物相容性和 pH 敏感的药物纳米载体。成功地用戊二醛（GA）作为交联剂制备了包括 CS、PVP 和 α-FeO 的水凝胶。将 α-FeO 掺入 CS/PVP 水凝胶中提高了 pH 敏感性并开发了有益的水凝胶。FTIR 和 XRD 分析说明了聚合物-聚合物、聚合物-药物之间的物理相互作用以及制备的纳米复合材料的结晶行为。这些分析还证实了纳米复合材料结构中的化学键合。FE-SEM 分析表明 α-FeO 成功地浸渍到 CS/PVP 基质和球形结构中。为了阐明载药纳米复合材料（CS/PVP/α-FeO/Dox）的粒径分布和表面电荷，进行了 DLS 和 zeta 分析。结果表明纳米复合材料的平均粒径约为 247nm。研究了载药 CS/PVP/α-FeO 纳米复合材料和 CS/PVP/Dox 的释放行为和动力学。此外，还研究了 α-FeO 对 CS/PVP/α-FeO/Dox 纳米复合材料释放的影响。结果表明，阿霉素的包封率增加，具有缓慢释放和保留效果等有益的释放行为。从这种载药纳米复合材料的释放中揭示了药物的出色 pH 敏感性和控制释放。此外，还研究了体外细胞毒性和细胞凋亡，以识别生物特性。这些分析表明，载药纳米复合材料在存在 α-FeO 的情况下对 MCF-7 细胞具有高抑制作用，并证明了赤铁矿的抗癌作用。总的来说，这项研究证实了 CS/PVP/α-FeO 纳米复合材料是一种潜在的药物控释候选材料。
